Investment House LLC Sells 4,868 Shares of Bristol-Myers Squibb (NYSE:BMY)

Investment House LLC reduced its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 19.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 19,995 shares of the biopharmaceutical company’s stock after selling 4,868 shares during the quarter. Investment House LLC’s holdings in Bristol-Myers Squibb were worth $1,026,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. OFI Invest Asset Management acquired a new position in Bristol-Myers Squibb during the third quarter worth $25,000. Milestone Investment Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $27,000. Blue Bell Private Wealth Management LLC increased its position in shares of Bristol-Myers Squibb by 61.5% in the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 200 shares during the last quarter. Legacy Financial Group LLC bought a new stake in Bristol-Myers Squibb during the third quarter worth about $39,000. Finally, Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the fourth quarter valued at approximately $40,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on BMY shares. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $77.00 to $54.00 in a research report on Tuesday, February 6th. BMO Capital Markets cut their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday. Barclays lowered their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Finally, Wells Fargo & Company increased their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $44.67 on Tuesday. The business has a 50-day simple moving average of $50.93 and a two-hundred day simple moving average of $51.02. Bristol-Myers Squibb has a 12-month low of $44.34 and a 12-month high of $69.10. The stock has a market cap of $90.55 billion, a PE ratio of -14.40, a PEG ratio of 15.47 and a beta of 0.39. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.05 EPS. Analysts anticipate that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.37%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.